




START₂ Registry

Emilia Antonucci












Bologna 25-26 gennaio 2018



Published Articles



-  Cini M et al. Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register. *International Journal of Laboratory Hematology*, 2018
-  Patti G, et al. Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Ricottini E, Marcucci R. Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome. *PLoS One*. 2017
-  Gentian D, Pengo V et al. Warfarin prescription in patients with non-valvular atrial fibrillation and one non-gender related risk factor (CHA2DS2VASc 1 or 2): a treatment dilemma. *Cardiovascular Therapeutics*, 2017
-  Palareti G, Antonucci E, Migliaccio L, et al on behalf of the centres participating in the FCSA-START-Register (The ISCOAT 2016 study). Vitamin K Antagonist Therapy: Changes in the Treated Populations and in Management Results in Italian Anticoagulation Clinics Compared with those recorded 20 years ago. *Intern and Emerg Med*, 2017
-  Poli D, Antonucci E, Pengo V, et al. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in patients with atrial fibrillation. *Am J Cardiol* 2017
-  Testa S, Tripodi A, Legnani C, et al; START-Laboratory Register. Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. *Thromb Res* 2016
-  Testa S, Legnani C, Tripodi A, et al. Poor comparability of coagulation screening test with specific measurement in patients on direct oral anticoagulants: results from a multicenter/multiplatform study. *J Thromb Haemost* 2016
-  Palareti G, Antonucci E, Lip GY, et al. The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE. A real-life inception cohort study. *Thromb Haemost*. 2016
-  Antonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, Marongiu F, Palareti G; START-Register. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. *PLoSOne* 2015

3° CONVEGNO DI ANTICOAGULAZIONE.it

“ ANTICOAGULAZIONE | Attualità cliniche e di laboratorio. Aspetti sociali ”

BOLOGNA 25-26 GENNAIO 2018 Savoia Hotel Regency - Via del Pilastro 2, 40127 Bologna




Submitted Articles


- 🌀 Testa S et al. Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Events Registry
- 🌀 Testa S et al Low Drug Levels And Thrombotic Complications In High Risk Atrial Fibrillation Patients Treated With Direct Oral Anticoagulants
- 🌀 Poli D et al. Mechanical Prosthetic Heart Valves: quality of anticoagulation and thromboembolic risk. The observational multicentre PLECTRUM Study.
- 🌀 Poli D et al. High risk for reoperation among patients with bioprosthetic heart valves and indication for long-term anticoagulation.
- 🌀 Cirillo P et al. Gender-related differences on the choice of antiplatelet therapy and its impact on one-year clinical outcome in patients presenting with Acute Coronary Syndrome: Insights from the START Antiplatelet Registry



Enrolled patients (January 2018)



All Patients



DOACs Patients



START-Valvole
3030 pts

START₂
REGISTRY

16192 patients



START2 REGISTRY

13072
patients



FCSA START



START2 POST-VTE

102
patients



START EVENTI

231
events



START ANTIPLATELET

1429
patients



START LABORATORIO

573
patients

MAS-Study



FADOI START

1358
patients



START2-POST VTE

Cosa fare dopo un periodo standard di anticoagulazione in un paziente con un recente episodio di VTE ?

Obiettivi

- Registrazione approcci, decisioni e risultati da parte dei professionisti nella real-life italiana
- Come i professionisti valutano il paziente: quali le caratteristiche esaminate, (rischio emorragico, recidiva)
- Cosa decidono in merito alla terapia
- Sulla base di quali fattori e quali ragionamenti
- Cosa succede nel follow-up dei pazienti

Promosso da: **Fondazione Arianna Anticoagulazione**
Centro Coordinatore: **Angiologia, Bologna**

start2.postvte@fondazionearianna.org





START2-POST VTE

December 2017


Sperimentatori

Pazienti

Start2 POST-VTE	
Pazienti Arruolati	102
Maschi	73%
Età (mediana)	70 (22-85)
Evento Indice	
TVP	70%
TVP+EP	12%
EP	8%

Start2 POST-VTE	
Adesioni	115
Comitati Etici Approvazioni	21
In seduta	16
Sperimentatori che devono restituire i documenti firmati	5
	48

Modalità di sospensione




start2.postvte@fondazionearianna.org




Per quali pazienti i centri FCSA preferiscono AVK o NAO

Atrial fibrillation patients




Naive Patients
3872

VTE patients



Switched Patients
(1254)



Data from 29 FCSA AC from June 2013 to May 2017

3782 AF pts (2566 AVK - 1216 DOACs)
1572 VTE pts (619 AVK - 953 DOACs)

AF patients

- DOACs preferiti in anziani e pregresse complicanze (Ictus, EM); pochi con IR severa
- Switch: non rilevante il TTR; più frequente se complicanze (Ictus, EM)


TEV Patients

- DOACs preferiti in giovani e in TVP; molto meno se EP, meno se fattori di rischio, pochi con IR severa
- Switch: non rilevante il TTR; meno anziani; più frequenti EM; molto frequenti se trombofilia e recidiva





ACCP score to assess the risk of bleeding during anticoagulation: application to real-life data from the START2-REGISTRY





➤ 2263 pz, 3130 a-p

➤ 48 emorragie registrate (1.53 pt-y):

- 28 MB

- 20 NMCRB

ACCP score



ORTHO-START

CHIRURGIA ELETTIVA ED IN EMERGENZA (PROTESI ANCA- GINOCCHIO; FRATTURA FEMORE) IN PAZIENTI ANTICOAGULATI

Scopo generale: osservazione e la registrazione dei dati relativi alla gestione peri-operatoria e alle complicanze in pazienti trattati con farmaci anticoagulanti e/o antiaggreganti per contribuire al miglioramento della gestione peri-operatoria nel paziente fragile come il paziente anziano con pluripatologie e plurimedicato, al fine di ridurre le complicanze e la mortalità a breve e medio termine.

e.grandone@operapadrepio.it



<http://www.start-register.org>



Progetto Nominato
START2 Registry
Fondazione Arianna Anticoagulazione



Start₂-Registry

**Emilia Antonucci
Ludovica Migliaccio
Serena Zorzi**

e-mail: start2@fondazionearianna.org

**www.fondazionearianna.org www.ariannafoundation.org
www anticoagulazione.it**

3° CONVEGNO DI ANTICOAGULAZIONE.it

“ ANTICOAGULAZIONE | Attualità cliniche e di laboratorio. Aspetti sociali ”

BOLOGNA 25-26 GENNAIO 2018 Savoia Hotel Regency - Via del Pilastro 2, 40127 Bologna